---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-23-026058"
form_type: "8-K"
ticker: "INBP"
cik: "0001016504"
company_name: "INTEGRATED BIOPHARMA INC"
filed_at: "2023-09-15T23:59:59+00:00"
generated_at: "2026-06-10T15:49:58.903311+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Integrated BioPharma FY2023 revenue down 9.8%; net loss of $34K vs prior year net income $3.8M

## Summary
- Q4 revenue $13.0M (-2.3% YoY); operating income $79K vs $438K; net income $40K ($0.00 EPS).
- FY2023 revenue $50.7M (-9.8%); operating income $120K vs $2.7M; net loss $34K ($0.00 EPS).
- Diluted EPS $0.00 for both Q4 and FY; prior year $0.05 and $0.12 respectively.
- Contract Manufacturing Segment contributed 95% of total revenue; two largest customers accounted for ~89%.
- Warehousing/distribution business segment grew slightly as a percentage of total revenue.

## SEC filing metadata
- accession: 0001437749-23-026058
- form_type: 8-K
- ticker: INBP
- cik: 0001016504
- company_name: INTEGRATED BIOPHARMA INC
- filed_at: 2023-09-15T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1016504/000143774923026058/0001437749-23-026058-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1016504/000143774923026058/inbp20230913_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-23-026058
- JSON: https://secwatch.observer/filing/0001437749-23-026058.json
- Plain text: https://secwatch.observer/filing/0001437749-23-026058.txt

## Key facts
- Earnings Releases
  INTEGRATED BIOPHARMA INC reported fiscal year ended June 30, 2023 results: revenue $50.7 million, net income a net loss of approximately $34,000 or $0.00 per share of common stock, EPS $0.00 per share of common stock.
  - Period: fiscal year ended June 30, 2023
  - Revenue: $50.7 million
  - Net income: a net loss of approximately $34,000 or $0.00 per share of common stock
  - EPS: $0.00 per share of common stock
  - Result: reported results
  source text: Revenues for the fiscal year ended June 30, 2023 were $50.7 million compared to $56.2 million for the fiscal year ended June 30, 2022, a decrease of $5.5 million or 9.8%.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1016504/000143774923026058/0001437749-23-026058-index.htm
- Earnings Releases
  INTEGRATED BIOPHARMA INC reported quarter ended June 30, 2023 results: revenue $13.0 million, net income approximately $40,000 or $0.00 per share of common stock, EPS $0.00 per share of common stock.
  - Period: quarter ended June 30, 2023
  - Revenue: $13.0 million
  - Net income: approximately $40,000 or $0.00 per share of common stock
  - EPS: $0.00 per share of common stock
  - Result: reported results
  source text: Revenue for the quarter ended June 30, 2023 was $13.0 million compared to $13.3 million for the quarter ended June 30, 2022, a decrease of $0.3 million or 2.3%.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1016504/000143774923026058/0001437749-23-026058-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.